Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC) Radiance Biopharma has signed an exclusive license agreement with CSPC Megalith for the development and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities Sonnet BioTherapeutics announced its ADC platform, leveraging its FHAB domain for flexible payload capacity and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 20 Feb 2025: Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer Myris Therapeutics, formerly BioHybrid Solutions, has emerged from stealth with a focus […]
Weekly Digest – August 2024 Weekly Digest – August 2024 22 Aug 2024: PADCEV® (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced bladder cancer Health Canada has approved PADCEV® (enfortumab vedotin) in combination with pembrolizumab […]
Weekly Digest – August 2024 Weekly Digest – August 2024 20 Aug 2024: Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline tinkering continues Merck & Co. has agreed to pay $37.5 million to […]
Weekly Digest – August 2024 Weekly Digest – August 2024 20 Aug 2024: Denmark’s Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC Denmark’s Adcendo has secured the ex-China rights to a preclinical antibody-drug conjugate (ADC) candidate from Multitude Therapeutics in […]
Weekly Digest – August 2024 Weekly Digest – August 2024 20 Aug 2024: FDA greenlights BioNTech/Medilink’s cancer trial at lower dose after deaths The FDA has allowed BioNTech and Medilink to resume their Phase I oncology trial of BNT326/YL202, a […]
Weekly Digest – August 2024 Weekly Digest – August 2024 20 Aug 2024: GSK5764227 Gains FDA Breakthrough Therapy Designation in ES-SCLC The FDA has granted breakthrough therapy designation to GSK5764227, a B7-H3–targeted antibody-drug conjugate, for treating extensive-stage small cell lung […]
Weekly Digest – August 2024 Weekly Digest – August 2024 19 Aug 2024: ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer ENHERTU® has been granted Breakthrough Therapy Designation in the U.S. […]
Weekly Digest – August 2024 Weekly Digest – August 2024 19 Aug 2024: ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy The European Medicines […]
